Teon Therapeutics, a United States-based biopharmaceutical company, announced on Tuesday that it has named Glen Giovannetti as its new director.

Giovannetti has more than 36 years of leadership experience, industry expertise and board governance credentials subsequent to his retirement from Ernst & Young in December 2020.

Ken Horne, president and chief operating officer of Teon Therapeutics, said, 'We are excited to have Glen joining our board. His experience as lead partner on numerous IPOs and M&A transactions in the biotech industry will be invaluable for Teon as we navigate future growth opportunities.'